Jeffrey S. Parkin

Array ( [id] => 14883553 [patent_doc_number] => 10421803 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits [patent_app_type] => utility [patent_app_number] => 15/115547 [patent_app_country] => US [patent_app_date] => 2015-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 60 [patent_no_of_words] => 19482 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15115547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15006279 [patent_doc_number] => 10449245 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-22 [patent_title] => Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent [patent_app_type] => utility [patent_app_number] => 15/114296 [patent_app_country] => US [patent_app_date] => 2015-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20689 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15114296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11270513 [patent_doc_number] => 20160333060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'ANTI-VIRAL CNIDARINS' [patent_app_type] => utility [patent_app_number] => 15/110156 [patent_app_country] => US [patent_app_date] => 2015-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 24415 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15110156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11120673 [patent_doc_number] => 20160317648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'CAP260, CAP174 AND K0224 HIV-1 ENVELOPES, PEPTIDE AND COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 15/105214 [patent_app_country] => US [patent_app_date] => 2014-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 8187 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15105214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10346224 [patent_doc_number] => 20150231229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'REPLICATION-COMPETENT ADENOVIRAL VECTORS' [patent_app_type] => utility [patent_app_number] => 14/571942 [patent_app_country] => US [patent_app_date] => 2014-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16544 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14571942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11809718 [patent_doc_number] => 09714279 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-25 [patent_title] => 'HIV vpr-specific T-cell receptors' [patent_app_type] => utility [patent_app_number] => 14/560314 [patent_app_country] => US [patent_app_date] => 2014-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 34 [patent_no_of_words] => 9620 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14560314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318827 [patent_doc_number] => 20150203830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'COMPOSITIONS COMPRISING NUCLEIC ACIDS ENCODING HIV-1 REVERSE TRANSCRIPTASE CTL EPITOPES' [patent_app_type] => utility [patent_app_number] => 14/531540 [patent_app_country] => US [patent_app_date] => 2014-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13895 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14531540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11040166 [patent_doc_number] => 20160237122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-18 [patent_title] => 'FUSION PROTEIN FOR HIV-1 GP120 ANTIGEN DETECTION' [patent_app_type] => utility [patent_app_number] => 15/029152 [patent_app_country] => US [patent_app_date] => 2014-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9630 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15029152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17177381 [patent_doc_number] => 11154610 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => Immunogenic compositions comprising FIV and HIV gag antigens [patent_app_type] => utility [patent_app_number] => 14/511864 [patent_app_country] => US [patent_app_date] => 2014-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 42 [patent_no_of_words] => 13359 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14511864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10240481 [patent_doc_number] => 20150125476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-07 [patent_title] => 'IMMUNOGENIC PEPTIDES AND POLYPEPTIDES FOR PROTECTION AGAINST HIV INFECTION' [patent_app_type] => utility [patent_app_number] => 14/508669 [patent_app_country] => US [patent_app_date] => 2014-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10679 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14508669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16183552 [patent_doc_number] => 10716845 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-21 [patent_title] => Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same [patent_app_type] => utility [patent_app_number] => 15/026391 [patent_app_country] => US [patent_app_date] => 2014-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 26814 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15026391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11016826 [patent_doc_number] => 20160213779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-28 [patent_title] => 'ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)' [patent_app_type] => utility [patent_app_number] => 15/025961 [patent_app_country] => US [patent_app_date] => 2014-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 34125 [patent_no_of_claims] => 89 [patent_no_of_ind_claims] => 33 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15025961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11005292 [patent_doc_number] => 20160202243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-14 [patent_title] => 'MITOCHONDRIA AND HUMAN IMMUNODEFIENCY VIRUS TYPE 1 TRANSMISSION' [patent_app_type] => utility [patent_app_number] => 14/499902 [patent_app_country] => US [patent_app_date] => 2014-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 13428 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14499902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13116463 [patent_doc_number] => 10076567 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-18 [patent_title] => MPER-liposome conjugates and uses thereof [patent_app_type] => utility [patent_app_number] => 15/024600 [patent_app_country] => US [patent_app_date] => 2014-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 69 [patent_no_of_words] => 12375 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15024600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11289118 [patent_doc_number] => 20160339051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-24 [patent_title] => 'HIV-1 MOTHER-TO-CHILD TRANSMISSION CORRELATES OF PROTECTION AND VACCINE' [patent_app_type] => utility [patent_app_number] => 15/025031 [patent_app_country] => US [patent_app_date] => 2014-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 27268 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15025031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9917133 [patent_doc_number] => 20150072339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'METHODS AND KITS FOR QUANTIFYING THE REMOVAL OF MOCK VIRUS PARTICLES FROM A PURIFIED SOLUTION' [patent_app_type] => utility [patent_app_number] => 14/481364 [patent_app_country] => US [patent_app_date] => 2014-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12479 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14481364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9910180 [patent_doc_number] => 20150065381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'METHODS OF IDENTIFYING NOVEL HIV-1 IMMUNOGENS' [patent_app_type] => utility [patent_app_number] => 14/478463 [patent_app_country] => US [patent_app_date] => 2014-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 19100 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14478463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11929788 [patent_doc_number] => 09796773 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-24 [patent_title] => 'Neutralizing antibodies that bind to the HIV-1 Env V2 critical neutralization domain' [patent_app_type] => utility [patent_app_number] => 14/463040 [patent_app_country] => US [patent_app_date] => 2014-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 13346 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14463040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10945845 [patent_doc_number] => 20140348866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-27 [patent_title] => 'GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV' [patent_app_type] => utility [patent_app_number] => 14/460517 [patent_app_country] => US [patent_app_date] => 2014-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 27479 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14460517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13182629 [patent_doc_number] => 10106818 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Dual-color HIV reporter system for the detection of latently-infected cells [patent_app_type] => utility [patent_app_number] => 14/910665 [patent_app_country] => US [patent_app_date] => 2014-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 10 [patent_no_of_words] => 40730 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14910665 [rel_patent_id] =>[rel_patent_doc_number] =>)